Vivotif® -: A 'magic shield' for protection against typhoid fever and delivery of heterologous antigens

被引:24
作者
Gentschev, Ivaylo
Spreng, Simone
Sieber, Heike
Ures, Jose
Mollet, Fabian
Collioud, Andre
Pearman, Jon
Griot-Wenk, Monika E.
Fensterle, Joachim
Rapp, Ulf R.
Goebel, Werner
Rothen, Simon A.
Dietrich, Guido
机构
[1] Berna Biotech Ltd, CH-3018 Bern, Switzerland
[2] Univ Wurzburg, Inst MSZ, Wurzburg, Germany
[3] Univ Wurzburg, Dept Microbiol, Wurzburg, Germany
关键词
live bacterial vaccines; Salmonella typhi Ty21a; Escherichia coli; haemolysin secretion system; vaccine carrier;
D O I
10.1159/000100515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The attenuated Salmonella typhi strain Ty21a is the main constituent of Vivotif((R)), the only attenuated live oral vaccine against typhoid fever. In comparison with antibiotics, the 'magic bullets' which Paul Ehrlich was striving for to treat infectious diseases, this vaccine should be viewed as a 'magic shield', because rather than treating typhoid fever after the infection has started, immunisation with this vaccine strain prevents infection and disease by the induction of specific immune responses. Ty21a is also an attractive carrier for the delivery of heterologous antigens. Recently, we successfully used Ty21a for antigen delivery via the haemolysin secretion system of Escherichia coli, which allows efficient protein secretion from the carrier bacteria. Copyright (c) 2007 S. Karger AG, Basel
引用
收藏
页码:177 / 180
页数:4
相关论文
共 39 条
[1]  
*ADV COMM IMM PRAC, 1994, MMWR-MORBID MORTAL W, V43, P1
[2]  
[Anonymous], VACCINES
[3]   Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002 [J].
Begier, EM ;
Burwen, DR ;
Haber, P ;
Ball, R .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (06) :771-779
[4]   EFFICACY OF ONE OR 2 DOSES OF TY21A SALMONELLA-TYPHI VACCINE IN ENTERIC-COATED CAPSULES IN A CONTROLLED FIELD TRIAL [J].
BLACK, RE ;
LEVINE, MM ;
FERRECCIO, C ;
CLEMENTS, ML ;
LANATA, C ;
ROONEY, J ;
GERMANIER, R .
VACCINE, 1990, 8 (01) :81-84
[5]   Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers [J].
Bumann, D ;
Metzger, WG ;
Mansouri, E ;
Palme, O ;
Wendland, M ;
Hurwitz, R ;
Haas, G ;
Aebischer, T ;
von Specht, BU ;
Meyer, TF .
VACCINE, 2001, 20 (5-6) :845-852
[6]   Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma (S)) regulon [J].
Coynault, C ;
RobbeSaule, V ;
Norel, F .
MOLECULAR MICROBIOLOGY, 1996, 22 (01) :149-160
[7]  
Dietrich G, 2003, CURR OPIN MOL THER, V5, P10
[8]   Experience with registered mucosal vaccines [J].
Dietrich, G ;
Griot-Wenk, M ;
Metcalfe, IC ;
Lang, AB ;
Viret, JF .
VACCINE, 2003, 21 (7-8) :678-683
[9]   The molecular mechanisms of severe typhoid fever [J].
Everest, P ;
Wain, J ;
Roberts, M ;
Rook, G ;
Dougan, G .
TRENDS IN MICROBIOLOGY, 2001, 9 (07) :316-320
[10]   COMPARATIVE EFFICACY OF 2, 3, OR 4 DOSES OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULES - A FIELD TRIAL IN AN ENDEMIC AREA [J].
FERRECCIO, C ;
LEVINE, MM ;
RODRIGUEZ, H ;
CONTRERAS, R .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (04) :766-769